ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

CHO cell

Also written as “Recombinant new coronavirus vaccine (CHO cell) group”, “Recombinant Zoster Vaccine (CHO Cell)” and “Recombinant two-component COVID-19 vaccine (CHO cell)”.

Its studies are mostly in COVID-19 · Herpes Zoster · Coronavirus Infections · Kidney Failure, Chronic, led by 7 companies.

Drug pageCHO cell: every studyMany companies study it; this page follows only the 29 they lead. All 35 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 28, 202229 company-led studies, 6 open or runningNext primary completion: Jul 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chongqing Zhifei Biological Productsits history only121 open or runningphase 4since Mar 28, 2022Jun 16, 2020none ahead
Jiangsu Rec-Biotechnologyits history only50 open or runningphase 3since May 30, 2022Mar 19, 2021none ahead
MAXVAX Biotechnology Limited Liabilityits history only54 open or runningphase 3since Jun 2, 2024Jun 2, 2024Dec 31, 2027phase 3 · NCT07293065
3SBioits history only20 open or runningphase 3since Jan 13, 2022May 10, 2019none ahead
Guangzhou Patronus Biotechits history only20 open or runningphase 3since Dec 23, 2022Dec 23, 2022none ahead
Sinopharm20 open or runningphase 2since Apr 24, 2021Apr 24, 2021none ahead
CSPC Pharmaceutical Groupits history only11 open or runningphase 2since Oct 19, 2026Oct 19, 2026Jul 31, 2027phase 2 · NCT07892989

Also a collaborator on its studies: Yantai Patronus Biotech and Iqvia Pty.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 24, 2021First study: phase 2 study in COVID-19First studyNCT04869592 · 3,100 enrolled · China
  2. Aug 30, 2021Phase 2 study in Coronavirus InfectionsNCT05033847 · 1,800 enrolled · United Arab Emirates

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Sinopharm leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05033847Coronavirus Infections · United Arab Emirates2UNKNOWNNov 20231,800
NCT04869592COVID-19 · China2CompletedAug 29, 20233,100

How it is read

Names in the registry

  • “Recombinant new coronavirus vaccine (CHO cell) group”, 5 entries
  • “Recombinant Zoster Vaccine (CHO Cell)”, 3 entries
  • “Recombinant two-component COVID-19 vaccine (CHO cell)”, 3 entries
  • “Recombinant RSV Vaccine (CHO Cell)”, 2 entries
  • “Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.